XLV241206C161000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
UnitedHealth Group Issued 2025 Guidance Ahead Of Now Stopped Investor Conference
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Incyte Gains Amid Takeover Speculation
'UnitedHealthcare CEO Fatally Shot In Midtown: Sources' - PIX11
Eli Lilly and Co announced the comparative trial results: Zepbound's weight-loss effect is better than Novo Nordisk's Wegovy.
eli lilly and co announced on Wednesday that in a comparative trial, its weight loss drug Zepbound had a greater weight loss effect than the competitor novo-nordisk a/s's similar drug Wegovy; eli lilly is still evaluating the trial results, the company stated that it plans to publish them in a peer-reviewed journal and present them at medical conferences next year.
Better than Wegovy! eli lilly and co's weight loss drug Zepbound averaged a 20% weight loss over 72 weeks, with a 2.5% pre-market surge.
Participants using Wegovy from novo-nordisk a/s only experienced a 14% reduction. This result presents eli lilly and co with an opportunity to surpass, especially with the obesity drug market expected to reach 130 billion USD by the end of this decade.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Powell Speech
Leading And Lagging Sectors For December 4, 2024
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
US Morning News Call | Stock Index Futures Climb on Positive Earnings, Focus Shifts to Upcoming Speech by Powell
Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
UnitedHealth Group Introduces FY25 Guidance, Sees EPS $29.50-$30.00 Vs $29.92 Est.; Revenue $450B-$455B Vs $431.435B Est.
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Check Out What Whales Are Doing With UNH
Nasdaq, S&P Ebb Near Record Highs, Dow Slips as JOLTS Report Kicks off Run of Jobs Data
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock